Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 8Cytokine Release Syndrome 3Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neurilemmoma 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × siltuximab × Clear all
NCT01024036 2018-03-21

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Janssen Research & Development, LLC

Phase 2 Completed
79 enrolled 20 charts

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Neoplasms

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Centocor, Inc.

Phase 2 Terminated
106 enrolled 13 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡